Study of Montelukast to Prevent Liver Enzyme Increases in Adults with Dengue Infection

What this Trial Is About

Dengue is a serious and growing health problem in tropical regions, affecting nearly 4 billion people worldwide with about 400 million infections annually. It often leads to liver problems, including elevated liver enzymes that are linked to more severe disease and complications such as shock, bleeding, and kidney failure. Researchers are studying whether the drug montelukast can help reduce these liver enzyme elevations in adults with dengue, potentially improving outcomes by addressing the underlying inflammation and plasma leakage caused by leukotrienes. This trial compares montelukast, given as a 10 mg oral tablet daily for up to 10 days or until the patient recovers, to a placebo given on the same schedule. The study is randomized, double-blind, and placebo-controlled, aiming to assess montelukasts effect on liver enzyme levels and safety in adult dengue patients. Participants will be admitted to the hospital and monitored closely during the treatment period. Participants will be evaluated from enrollment through the treatment period, focusing on serum transaminase levels on the day of recovery, along with secondary outcomes such as length of hospital stay, rates of severe dengue and shock, and blood tests including hematocrit and platelet counts. Safety and adverse events will also be monitored. The total treatment and follow-up duration is up to 10 days or until recovery as determined by the attending physicians.

Efficacy of Montelukast in Preventing Transaminase Elevation in Adult Dengue Patients